Top

Published in:

01-10-2016 | Original Article

Concordance analysis and diagnostic test accuracy review of IDH1 immunohistochemistry in glioblastoma

Authors: Jung-Soo Pyo, Nae Yu Kim, Roy Hyun Jai Kim, Guhyun Kang

Published in: Brain Tumor Pathology | Issue 4/2016

Abstract

The study investigated isocitrate dehydrogenase (IDH) 1 immunohistochemistry (IHC) positive rate and concordance rate between IDH1 IHC and molecular test in glioblastoma. The current study included 1360 glioblastoma cases from sixteen eligible studies. Meta-analysis, including subgroup analysis by antibody clones and cut-off values, for IDH1 IHC positive rate was conducted. In addition, we performed a concordance analysis and diagnostic test accuracy review between IDH1 IHC and molecular tests. The estimated rates of IDH1 IHC were 0.106 [95 % confidence interval (CI) 0.085–0.132]. The IDH1 IHC positive rate of primary and secondary glioblastomas was 0.049 (95 % CI 0.023–0.99) and 0.729 (95 % CI 0.477–0.889), respectively. The overall concordance rate between IDH1 IHC and molecular test was 0.947 (95 % CI 0.878–0.978). In IDH1 IHC-positive and negative subgroups, the concordance rate was 0.842 (95 % CI 0.591–0.952) and 0.982 (95 % CI 0.941–0.995), respectively. The pooled sensitivity and specificity for IDH1 IHC were 1.00 (95 % CI 0.82–1.00) and 0.99 (95 % CI 0.96–1.00), respectively. IDH1 IHC is an accurate test for IDH1 mutation in glioblastoma patients. Further cumulative studies for evaluation criteria of IDH1 IHC will determine how to best apply this approach in daily practice.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Figarella-Branger D, Perry A, Reifenberger G, von Deimling A (2016) WHO classification of tumours of the central nervous system, 4th edn. International Agency for Research on Cancer, Lyon

Capper D, Weissert S, Balss J, Capper D, Weissert S, Balss J (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245–254CrossRefPubMed

Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812CrossRefPubMedPubMedCentral

Turcan S, Rohle D, Goenka A et al (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483(7390):479–483CrossRefPubMedPubMedCentral

Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas. Acta Neuropathol 118:469–474CrossRefPubMed

Amelot A, De Cremoux P, Quillien V, Polivka M, Adle-Biassette H, Lehmann-Che J, Françoise L, Carpentier AF, George B, Mandonnet E, Froelich S (2015) IDH-mutation is a weak predictor of long-term survival in glioblastoma patients. PLoS One 10:e0130596CrossRefPubMedPubMedCentral

Montgomery RM, Queiroz Lde S, Rogerio F (2015) EGFR, p53, IDH-1 and MDM2 immunohistochemical analysis in glioblastoma: therapeutic and prognostic correlation. Arq Neuropsiquiatr 73:561–568CrossRefPubMed

Kurian KM, Haynes HR, Crosby C, Hopkins K, Williams M (2013) IDH mutation analysis in gliomas as a diagnostic and prognostic biomarker. Br J Neurosurg 27:442–445CrossRefPubMed

Ogura R, Tsukamoto Y, Natsumeda M, Isogawa M, Aoki H, Kobayashi T, Yoshida S, Okamoto K, Takahashi H, Fujii Y, Kakita A (2015) Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas. Neuropathology 35:324–335CrossRefPubMed

10.

Shin JH, Lee YS, Hong YK, Kang CS (2013) Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas. J Neurooncol 115:333–341CrossRefPubMed

11.

Takano S, Tian W, Matsuda M, Yamamoto T, Ishikawa E, Kaneko MK, Yamazaki K, Kato Y, Matsumura A (2011) Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol 28:115–123CrossRefPubMed

12.

Appin CL, Gao J, Chisolm C, Torian M, Alexis D, Vincentelli C, Schniederjan MJ, Hadjipanayis C, Olson JJ, Hunter S, Hao C, Brat DJ (2013) Glioblastoma with oligodendroglioma component (GBM-O): molecular genetic and clinical characteristics. Brain Pathol 23:454–461CrossRefPubMedPubMedCentral

13.

Kawasoe T, Takeshima H, Yamashita S, Mizuguchi S, Fukushima T, Yokogami K, Yamasaki K (2015) Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme. J Neurosurg 122:317–323CrossRefPubMed

14.

Kim BY, Jiang W, Beiko J, Prabhu SS, DeMonte F, Gilbert MR, Sawaya R, Aldape KD, Cahill DP, McCutcheon IE (2014) Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing. J Neurooncol 118:405–412CrossRefPubMedPubMedCentral

15.

Lee KS, Choe G, Nam KH, Seo AN, Yun S, Kim KJ, Cho HJ, Park SH (2013) Immunohistochemical classification of primary and secondary glioblastomas. Korean J Pathol 47:541–548CrossRefPubMedPubMedCentral

16.

Nakashima S, Sugita Y, Miyoshi H, Arakawa F, Muta H, Ishibashi Y, Niino D, Ohshima K, Terasaki M, Nakamura Y, Morioka M (2016) Endothelin B receptor expression in malignant gliomas: the perivascular immune escape mechanism of gliomas. J Neurooncol 127:23–32CrossRefPubMed

17.

Popova SN, Bergqvist M, Dimberg A, Edqvist PH, Ekman S, Hesselager G, Ponten F, Smits A, Sooman L, Alafuzoff I (2014) Subtyping of gliomas of various WHO grades by the application of immunohistochemistry. Histopathology 64:365–379CrossRefPubMed

18.

Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, Schweizer L, Korshunov A, Jones DT, Hovestadt V, Mittelbronn M, Schittenhelm J, Herold-Mende C, Unterberg A, Platten M, Weller M, Wick W, Pfister SM, von Deimling A (2015) ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 129:133–146CrossRefPubMed

19.

Sipayya V, Sharma I, Sharma KC, Singh A (2012) Immunohistochemical expression of IDH1 in gliomas: a tissue microarray-based approach. J Cancer Res Ther 8:598–601CrossRefPubMed

20.

Yang Y, Mao Q, Wang X, Liu Y, Mao Y, Zhou Q, Luo J (2016) An analysis of 170 glioma patients and systematic review to investigate the association between IDH-1 mutations and preoperative glioma-related epilepsy. J Clin Neurosci 31:56–62CrossRefPubMed

21.

Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A (2006) Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 6:31CrossRefPubMedPubMedCentral

22.

Vigneswaran K, Neill S, Hadjipanayis CG (2015) Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification. Ann Transl Med 3:95PubMedPubMedCentral

23.

Appin CL, Brat DJ (2014) Molecular genetics of gliomas. Cancer J 20:66–72CrossRefPubMed

24.

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773CrossRefPubMedPubMedCentral

25.

Lin N, Yan W, Gao K, Wang Y, Zhang J, You Y (2014) Prevalence and clinicopathologic characteristics of the molecular subtypes in malignant glioma: a multi-institutional analysis of 941 cases. PLoS One 9:e94871CrossRefPubMedPubMedCentral

26.

Geiersbach K, Adey N, Welker N, Elsberry D, Malmberg E, Edwards S, Downs-Kelly E, Salama M, Bronner M (2016) Digitally guided microdissection aids somatic mutation detection in difficult to dissect tumors. Cancer Genet 209:42–49CrossRefPubMed

27.

Molinari F, Felicioni L, Buscarino M, De Dosso S, Buttitta F, Malatesta S, Movilia A, Luoni M, Boldorini R, Alabiso O, Girlando S, Soini B, Spitale A, Di Nicolantonio F, Saletti P, Crippa S, Mazzucchelli L, Marchetti A, Bardelli A, Frattini M (2011) Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res 17:4901–4914CrossRefPubMed

28.

Agarwal S, Sharma MC, Jha P, Pathak P, Suri V, Sarkar C, Chosdol K, Suri A, Kale SS, Mahapatra AK, Jha P (2013) Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. Neuro Oncol 15:718–726CrossRefPubMedPubMedCentral

29.

Pyo JS, Sohn JH, Kim WH (2016) Concordance rate between HER2 immunohistochemistry and in situ hybridization in gastric carcinoma: systematic review and meta-analysis. Int J Biol Markers 31:e1–e10PubMed

30.

Arita H, Narita Y, Matsushita Y, Fukushima S, Yoshida A, Takami H, Miyakita Y, Ohno M, Shibui S, Ichimura K (2015) Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas. Brain Tumor Pathol 32:22–30CrossRefPubMed

31.

Friedensdorf B, Göppert M, Sabel MC, Reifenberger G (2010) Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol 119:501–507CrossRefPubMed

Title: Concordance analysis and diagnostic test accuracy review of IDH1 immunohistochemistry in glioblastoma
Authors: Jung-Soo Pyo
Nae Yu Kim
Roy Hyun Jai Kim
Guhyun Kang
Publication date: 01-10-2016
Publisher: Springer Japan
Published in: Brain Tumor Pathology / Issue 4/2016
Print ISSN: 1433-7398
Electronic ISSN: 1861-387X
DOI: https://doi.org/10.1007/s10014-016-0272-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Concordance analysis and diagnostic test accuracy review of IDH1 immunohistochemistry in glioblastoma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2016

Genetic landscape of meningioma

Letter to the Editor: regarding “Lipomatous ependymoma: report of a rare differentiation pattern with a comprehensive review of literature”

Genetic mutations in high grade gliomas of the adult spinal cord

A case of papillary tumor of the pineal region with a long clinical history: molecular characterization and therapeutic consideration with review of the literature

Sarcoma-like tumor originating from oligodendroglioma

Atypical teratoid/rhabdoid tumors with multilayered rosettes in the pineal region